Cidara Therapeutics to Present at 10th ESWI Influenza Conference 2025GlobeNewswireOctober 10, 2025 SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)'s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.
Presentation details are summarized below:
Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study.
Presenter: Voon Ong, Ph.D.
Session: Late Breakers: Novel and Outstanding Discoveries
Session Date and Time: Thursday, October 23, 2025, 2:00-3:30 pm CET
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak(R) platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communications(628) 234-3889mfitzhugh@lifescicomms.com
COMTEX_469417127/2010/2025-10-10T08:00:00
SAN DIEGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have a late-breaking presentation at the European Scientific Working Group on Influenza (ESWI)'s 10th Influenza Conference taking place October 20-23, 2025 in Valencia, Spain.
Presentation details are summarized below:
Late-Breaking Abstract Title: Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study.
Presenter: Voon Ong, Ph.D.
Session: Late Breakers: Novel and Outstanding Discoveries
Session Date and Time: Thursday, October 23, 2025, 2:00-3:30 pm CET
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak(R) platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communications(628) 234-3889mfitzhugh@lifescicomms.com
COMTEX_469417127/2010/2025-10-10T08:00:00
0.00% $0.00
